MedTrace Logo

TRF-1101 Assessment in Sickle Cell Disease

NCT00773890 · Status: TERMINATED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 80

Last updated 2009-05-11

No results posted yet for this study

Summary

This study is designed to assess the safety, tolerability, and activity of TRF-1101 on microvascular blood flow, vascular endothelial injury, and vasoocclusive pain associated with sickle cell disease.

Conditions

Interventions

DRUG

TRF-1101

once daily treatment with 300 mg orally for 12 weeks

DRUG

Placebo

Daily treatment with TRF-1101 vehicle for 12 weeks

Sponsors & Collaborators

  • TRF Pharma, Inc

    lead INDUSTRY

Principal Investigators

  • Stephen H Embury, M.D. · TRF Pharma, Inc

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-07-31
Primary Completion
2009-05-31
Completion
2009-05-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00773890 on ClinicalTrials.gov